文献速递白血病

儿童B淋巴母细胞白血病中DUX4与PAX5alt亚型的临床特征差异

Distinct clinical characteristics of DUX4- and PAX5-altered childhood B-lymphoblastic leukemia.
PubMed 文献 · Blood Adv · 2021-01-01

该研究对MS2003和MS2010两项研究中377例儿童B-ALL进行全转录组RNA测序,发现DUX4(14%)和PAX5alt(10%)分别为第三和第四常见亚型。DUX4亚型虽初始治疗反应差且day-33 MRD不佳,但5年CIR仅8.9%、5年OS达97.8%;PAX5alt预后强烈依赖IKZF1共缺失状态。

要点

  • DUX4是儿童B-ALL第三常见亚型(14%),PAX5alt第四(10%)。
  • DUX4亚型初始反应差但总体预后良好,5年CIR 8.9%、5年OS 97.8%。
  • PAX5alt无IKZF1缺失者预后极佳(23例无复发),有共缺失者复发风险高。

核心结论

  • DUX4 B-ALL尽管初始反应差和day-33 MRD不佳,但总体结局良好。
  • PAX5alt B-ALL的预后强烈依赖于IKZF1是否共缺失。

研究设计与样本

  • 对MS2003和MS2010研究中377例儿童B-ALL进行全转录组RNA测序。

主要发现

  • DUX4为第三常见亚型(n=51,14%),PAX5alt为第四(n=36,10%)。
  • DUX4在day-33 MRD不佳患者中占最大遗传亚型(44例中12例)。
  • DUX4的5年CIR为8.9%(95%CI 2.8%-19.5%),5年OS为97.8%(95%CI 85.3%-99.7%)。
  • MS2003中DUX4患者day-8泼尼松龙外周血反应差者占21%,高于其他亚型(8%;P=.03)。
  • MS2010中DUX4亚型未观察到day-8外周血反应差(P=.03)。

临床怎么用

  • DUX4 B-ALL不应因初始反应差或MRD不佳而低估其良好总体预后。
  • PAX5alt B-ALL需检测IKZF1共缺失以分层预后,共缺失者可从治疗强化中获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Among the recently described subtypes in childhood B-lymphoblastic leukemia (B-ALL) were DUX4- and PAX5-altered (PAX5alt). By using whole transcriptome RNA sequencing in 377 children with B-ALL from the Malaysia-Singapore ALL 2003 (MS2003) and Malaysia-Singapore ALL 2010 (MS2010) studies, we found that, after hyperdiploid and ETV6-RUNX1, the third and fourth most common subtypes were DUX4 (n = 51; 14%) and PAX5alt (n = 36; 10%). DUX4 also formed the largest genetic subtype among patients with poor day-33 minimal residual disease (MRD; n = 12 of 44). But despite the poor MRD, outcome of DUX4 B-ALL was excellent (5-year cumulative risk of relapse [CIR], 8.9%; 95% confidence interval [CI], 2.8%-19.5% and 5-year overall survival, 97.8%; 95% CI, 85.3%-99.7%). In MS2003, 21% of patients with DUX4 B-ALL had poor peripheral blood response to prednisolone at day 8, higher than other subtypes (8%; P = .03). In MS2010, with vincristine at day 1, no day-8 poor peripheral blood response was observed in the DUX4 subtype (P = .03). The PAX5alt group had an intermediate risk of relapse (5-year CIR, 18.1%) but when IKZF1 was not deleted, outcome was excellent with no relapse among 23 patients. Compared with MS2003, outcome of PAX5alt B-ALL with IKZF1 codeletion was improved by treatment intensification in MS2010 (5-year CIR, 80.0% vs 0%; P = .05). In conclusion, despite its poor initial response, DUX4 B-ALL had a favorable overall outcome, and the prognosis of PAX5alt was strongly dependent on IKZF1 codeletion.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Li Z, Lee SHR, Chin WHN, et al. Distinct clinical characteristics of DUX4- and PAX5-altered childhood B-lymphoblastic leukemia. Blood Adv. 2021. PMID: 34547766. doi:10.1182/bloodadvances.2021004895

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。